AnGes, Inc.
4563 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 茨木市彩都あさぎ七丁目７番１５号
- Website:
- https://www.anges.co.jp/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
AnGes, Inc. is a pioneering biotechnology company based in Japan, recognized as a global leader in gene medicine. The company specializes in the development of innovative therapeutic solutions, leveraging advanced gene delivery technologies to address unmet medical needs. AnGes is particularly focused on areas such as chronic pain management and regenerative medicine, with ongoing research and clinical trials, including its NF-κB Decoy Oligo DNA for treating chronic intervertebral disc lumbago. Committed to advancing healthcare, AnGes collaborates with international partners to enhance its research capabilities and expedite the development of novel therapies, aiming to improve patient outcomes around the world.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-31 04:52 |
Inside Information Statement
臨時報告書
|
Japanese | 25.5 KB | |
| 2025-03-31 03:22 |
Internal Control over Financial Reporting
内部統制報告書－第26期(2024/01/01－2024/12/31)
|
Japanese | 23.7 KB | |
| 2025-03-31 03:18 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2025-03-31 03:17 |
Annual Report
有価証券報告書－第26期(2024/01/01－2024/12/31)
|
Japanese | 1.5 MB | |
| 2024-09-03 06:05 |
Regulatory News Service
訂正有価証券届出書（参照方式）
|
Japanese | 203.2 KB | |
| 2024-08-30 09:06 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 381.2 KB | |
| 2024-08-14 02:28 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-08-14 02:27 |
Interim Report
半期報告書－第26期(2024/01/01－2024/12/31)
|
Japanese | 725.7 KB | |
| 2024-05-14 02:27 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-05-14 02:25 |
Quarterly Report
四半期報告書－第26期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 457.7 KB | |
| 2024-03-29 01:45 |
Inside Information Statement
臨時報告書
|
Japanese | 24.0 KB | |
| 2024-03-29 01:43 |
Internal Control over Financial Reporting
内部統制報告書－第25期(2023/01/01－2023/12/31)
|
Japanese | 23.6 KB | |
| 2024-03-29 01:39 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2024-03-29 01:36 |
Annual Report
有価証券報告書－第25期(2023/01/01－2023/12/31)
|
Japanese | 1.6 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Idorsia Ltd | Switzerland | IDIA | |
|
ILIKA PLC | United Kingdom | IGE | |
|
Immuno-Biological Laboratories Co., Ltd. | Japan | 4570 | |
|
Indivior PLC | United Kingdom | INDV | |
|
Infant Bacterial Therapeutics | Sweden | IBT | |
|
Initiator Pharma A/S | Denmark | INIT | |
|
Intercure Ltd. | Israel | INCR | |
|
Intervacc AB | Sweden | IVACC | |
|
Ipsen | France | IPN | |
| JCR Pharmaceuticals Co.,Ltd. | Japan | 4552 |